Eye Institute surgeons selected to trial the commercial implantation of the Alcon Vivity.
Eye Institute’s Dr Shanu Subbiah and Dr Nick Mantell have been selected as the only two New Zealand surgeons to trial the commercial implantation of the Alcon Vivity. The Alcon Vivity is a new wave front corrected intraocular lens that offers excellent distance, intermediate and usable near vision with the side effect profile of a monofocal intraocular lens. For many this will see an innovative advancement in cataract and lens exchange treatment.
“ I like to think of this as a “lifestyle” intraocular lens implant to give cataract or lens exchange patients excellent distance and intermediate vision with useable reading or near vision. Most patients will benefit from reading glasses for prolonged near vision tasks.” – Dr Shanu Subbiah.
The Alcon Vivity is a novel intra-ocular implant that has performed excellently in preliminary clinical trials. Unlike many multifocus implants there are minimal vision side effects such as glare and halos particularly when driving at night. The quality of distance vision is also much better than the multifocus implants currently available worldwide.
“I am honoured that Alcon NZ have chosen Dr. Nick Mantell and myself to be the only ophthalmic surgeons in New Zealand to be allowed to use this implant before its official release which is likely to be in the third quarter of 2020.” – Dr Shanu Subbiah.
The ideal candidate for the Alcon Vivity is someone who seeks great quality distance and intermediate vision (computers, smartphones, and watches) but doesn’t mind using glasses for prolonged near vision tasks such as reading. The lens has a visual side effect profile that is very similar to standard single vision implants which remain the gold standard for quality of vision under all lighting conditions.
Leading ophthalmic surgeons, Dr Shanu Subbiah and Dr Nick Mantell will trial the commercial implantation of the Alcon Vivity from December, ahead of its official release later next year.